medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 1

<< Back Next >>

Ann Hepatol 2016; 15 (1)

Direct intrahepatic portocaval shunt for treatment of portal thrombosis and Budd-Chiari syndrome

Pedersen MR, Molloy P, Wood D, Seetharam A

Language: English
References: 17
Page: 127-130
PDF size: 233.66 Kb.


ABSTRACT

Budd-Chiari syndrome (BCS) refers to hepatic venous outflow obstruction that in severe cases can lead to acute liver failure prompting consideration of revascularization or transplantation. Here, a 22 year old female with angiographically proven BCS secondary to JAK2/V617F positive Polycythemia vera on therapeutic warfarin presented with acute liver failure (ALF). Imaging revealed a new, near complete thrombotic occlusion of the main portal vein with extension into the superior mesenteric vein. An emergent direct intrahepatic portocaval shunt (DIPS) was created and liver function promptly normalized. She has been maintained on rivaroxaban since that time. Serial assessment over 1 year demonstrated continued shunt patency and improved flow in the mesenteric vasculature on ultrasound as well as normal liver function. DIPS is a viable alternative in the treatment of ALF from BCS when standard recanalization is not feasible. Improved blood flow may also improve portal/mesenteric clot burden. While further investigation is needed, new targeted anticoagulants may be viable as a long term anticoagulation strategy.


REFERENCES

  1. Murad SD, Valla DC, de Greon PC, Zeitoun G, Hopsman JA, Haagsma EB, van Hoek B, et al. Determinants of survival and effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2003; 39: 500-8.

  2. Qi KS, Ren WR, Fan DM, Han GH. Selection of treatment modalities for Budd-Chiari syndrome in China: A preliminary survey of published literature. World J Gastroentol 2014; 20: 10628-36.

  3. Seijo S, Plessie A, Hoekstra J, Dell’Era A, Mandair D, Rifai K, Trebicka J, et al. Good long-term outcome of Budd-Chiari syndrome with step-wise management. Hepatology 2013; 57: 1962-8.

  4. Plessier A, Sibert A, Cosigny Y, Hakime A, Zappa M, Denninger MH, Condat B, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 2008; 44: 1308-16.

  5. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009. Hepatology 2010; 51: 1-16.

  6. Petersen BD, Clark TWI. Direct intrahepatic portocaval shunt. Tech Vasc Interventional Rad 2008; 11: 230-4.

  7. Srivastava S, Duncan M, Joseph A, Ong J, Duncan D, Younossi Z. Budd-Chiari syndrome (BCS) with mesenteric vein thrombosis (MVT) treated by direct intrahepatic portocaval shunt (DIPS) and mechanical thrombectomy. Am J Gastroenterol 2003; 98: S173-S174.

  8. Boyvat F, Harman A, Ozyer U, Aytekin C, Arat Z. Percutaneous sonographic guidance for TIPS in Budd-Chiari Syndrome: Direct sumulatenous puncture of the portal vein and inferior vena cava. AJR Am J Roentgenol 2008; 191: 560-4.

  9. Boyvat F, Aytekin C, Harman A, Ozin Y. Transjugular intrahepatic portosystemic shunt creation in Budd-Chiari Syndrome: Percutaneous ultrasound-guided direct simultaneous puncture of the portal vein and vena cava. Cardiovasc Interent Radiol 2006; 29: 857-61.

  10. Montano-Loza AJ, Tandon P, Kneteman N, Bailey R, Bain VG. Rotterdam score predicts early mortality in Budd-Chiari syndrome, and surgical shunting prolongs transplant-free survival. Aliment Pharmacol Ther 2009; 30: 1060-9.

  11. Gasparini D, Del Forno M, Sponza M, Branca B, Toniutto P, Marzio A, Pirisi M. Transjugular intrahepatic portosystemic shunt by direct transcaval approach in patients with acute and hyperacute Budd-Chiari syndrome. Eur J Gastroenterol Hepatol 2002; 14: 567-51.

  12. Quateen A, Pech M, Berg T, Bergk A, Podrabsky P, Felix R, Ricke J. Percutaneous transjugular direct porto-caval shunt in patients with Budd-Chiari syndrome. Cardiovasc Interven Radiol 2006; 29: 565-70.

  13. Jones C, Levy Y, Tong AW. Elevated serum erythropoietin in a patient with polycythemia presenting with Budd-Chiari syndrome. BMJ Case Rep. Published online: 1 December 2014. Doi: 10.1136/bcr-2014-205663.

  14. Janssen Pharmaceuticals Corp. Rivaroxaban. Titusville, NJ: Janssen Pharmaceuticals Corp.; 2015.

  15. Boehringer Ingelheim Pharmaceuticals, Inc. Dabigatran. Ridgefield, TC: Boehringer Ingelheim Pharmaceuticals, Inc.; 2015.

  16. Bristol-Myers Squibb Company. Apixaban. New York City, NY: Bristol-Myers Squibb Company; 2014.

  17. Mancuso A. An update on management of Budd-Chiari syndrome. Ann Hepatol 2014; 13: 323-6.




2020     |     www.medigraphic.com